| Name | Title | Contact Details |
|---|
BioStar Ventures continues to build a solid track record as an early-stage, value-added venture investor in disruptive cardiovascular and orthopaedic medical technologies by combining the insight of seasoned venture capitalists with the expertise of world-renowned medical thought leaders in clinical practice to attract unique deal flow, mitigate investment risk, optimize product development, and secure successful exit.
Prime Medicine was founded to bring the promise of gene editing to patients. We use Prime Editing, a next-generation technology that can “search and replace” to restore normal genetic function almost anywhere in the genome. Prime Editing searches to find the precise place in the genome to edit and replaces the segment of faulty DNA with a correct copy of DNA. A single Prime Editor can correct the individual mutations found across patients, meaning Prime Editing can potentially address more than 90 percent of known disease-causing genetic mutations.
Sera Prognostics is a leading proteomic and bioinformatics company dedicated to improving the lives of women and babies through precision biomarker-based tests designed to enhance pregnancy care. Sera’s vision is to deliver pivotal information in early pregnancy to physicians, to help them to improve the health of their patients and reduce costs of healthcare delivery. Sera’s PreTRM® Test reports to a physician the individualized risk of a pregnant woman to deliver prematurely, enabling earlier proactive interventions in patients with higher risk. Rigorous clinical validation of PreTRM® Test performance (accuracy of predicting premature delivery) was reported in the American Journal of Obstetrics & Gynecology in 2016 in a U.S. cohort of 5,501 patients across 11 centers. Preterm birth is defined as any birth before 37 weeks gestation and is a leading cause of illness and death in newborns. The 2020 March of Dimes Report Card shows that of nearly 4 million babies born annually in the U.S., more than one in ten is born prematurely. Prematurity is associated with a significantly increased risk of major long-term medical complications, including learning disabilities, cerebral palsy, chronic respiratory illness, intellectual disability, seizures, vision and hearing loss, and can generate significant cost throughout the lives of affected children. The annual U.S. health care costs to manage complications of prematurity were estimated at $31.5B for 2015. Sera is also developing a robust pipeline of innovative tests focused on other complications of pregnancy. Using its advanced proprietary mass spectrometry and bioinformatics platform technologies, Sera detects biologically important protein expression differences to build high performing predictions of risk for adverse pregnancy outcomes (including preterm birth, preeclampsia, gestational diabetes, growth restriction, and others).
Mango Materials produces biodegradable plastics from waste biogas (methane) that are economically competitive with conventional, oil-based plastics. Mango Materials produces poly-hydroxyalkanoate (PHA) powder, a valuable biopolymer that is converted into a variety of ecofriendly, plastic products such as children’s toys, electronic casings, water bottles, and food packaging containers. Due to a rising preference for green products, demand for biodegradable and non petroleum-based plastics is growing rapidly. Mango Materials uses affordable methane gas and a process that competes favorably with petroleum-based plastics to produce low-cost, biodegradable plastics.
harmagreen is a company focused on BIOTECH SCIENCES utilizing proprietary technologies and formulations in its state of the art CANNABIS BOTANY CENTER